Rapid desensitization for brentuximab vedotin (Adceteris^®) allergy: a case report.

Q2 Medicine

Clinical and Molecular Allergy Pub Date : 2018-10-29 eCollection Date: 2018-01-01 DOI:10.1186/s12948-018-0100-0

Attilio Di Girolamo, Marcello Albanesi, Alessandro Sinisi, Eustachio Nettis, Danilo Di Bona, Maria Filomena Caiaffa, Luigi Macchia

{"title":"Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: a case report.","authors":"Attilio Di Girolamo, Marcello Albanesi, Alessandro Sinisi, Eustachio Nettis, Danilo Di Bona, Maria Filomena Caiaffa, Luigi Macchia","doi":"10.1186/s12948-018-0100-0","DOIUrl":null,"url":null,"abstract":"Background: Brentuximab vedotin (BV) is an antibody-drug conjugate formed by an anti-CD30 chimeric IgG1 conjugated with monomethyl-auristatin-E. BV targets the CD30+ cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30+ cells BV exerts its cytotoxic effect via the monomethyl-auristatin-E moiety. So far, accounts on immediate adverse reactions to BV remain anecdotal. Moreover, few reports exist on desensitization for BV.Case presentation: A 20-year old male patient was diagnosed with Hodgkin lymphoma in July 2014. The first line treatment with adriblastine, bleomicine, vinblastine and dacarbazine lead to a partial remission. Thus, a treatment with BV was started. However, during the second BV infusion, he developed generalized urticaria and dyspnea. In order not to discontinue the treatment with BV, we performed a thorough allergological workup and designed a 12-step rapid desensitization protocol. Overall the desensitization procedure was well tolerated and no major adverse reactions occurred.Conclusion: Rapid desensitization is a suitable and safe option in the case of BV allergy and prevents the BV treatment withdrawal.","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"16 ","pages":"22"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-018-0100-0","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-018-0100-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 6

Abstract

Background: Brentuximab vedotin (BV) is an antibody-drug conjugate formed by an anti-CD30 chimeric IgG₁ conjugated with monomethyl-auristatin-E. BV targets the CD30⁺ cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30⁺ cells BV exerts its cytotoxic effect via the monomethyl-auristatin-E moiety. So far, accounts on immediate adverse reactions to BV remain anecdotal. Moreover, few reports exist on desensitization for BV.

Case presentation: A 20-year old male patient was diagnosed with Hodgkin lymphoma in July 2014. The first line treatment with adriblastine, bleomicine, vinblastine and dacarbazine lead to a partial remission. Thus, a treatment with BV was started. However, during the second BV infusion, he developed generalized urticaria and dyspnea. In order not to discontinue the treatment with BV, we performed a thorough allergological workup and designed a 12-step rapid desensitization protocol. Overall the desensitization procedure was well tolerated and no major adverse reactions occurred.

Conclusion: Rapid desensitization is a suitable and safe option in the case of BV allergy and prevents the BV treatment withdrawal.

查看原文本刊更多论文

brentuximab vedotin (Adceteris®)过敏的快速脱敏1例报告。

背景:Brentuximab vedotin (BV)是一种抗体-药物偶联物，由抗cd30嵌合IgG1与单甲基auristatin- e偶联而成。BV靶向CD30+细胞，这是霍奇金淋巴瘤和间变性大细胞淋巴瘤的特征。一旦与CD30+细胞结合，BV通过单甲基-auristatin- e片段发挥其细胞毒性作用。到目前为止，关于细菌性阴道炎的直接不良反应仍然是传闻。此外，很少有关于BV脱敏的报道。病例介绍:一名20岁男性患者于2014年7月被诊断为霍奇金淋巴瘤。阿布司汀、博洛美嗪、长春碱和达卡巴嗪的一线治疗导致部分缓解。因此，开始了BV治疗。然而，在第二次BV输注期间，他出现全身性荨麻疹和呼吸困难。为了不中断BV治疗，我们进行了彻底的过敏检查，并设计了12步快速脱敏方案。总体而言，脱敏过程耐受性良好，未发生重大不良反应。结论:快速脱敏是BV过敏患者安全、适宜的治疗方法，可防止BV治疗停药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Molecular Allergy Medicine-Immunology and Allergy

CiteScore

8.20

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable. At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response.